Progressive pseudorheumatoid dysplasia involving a novel WISP3 mutation and sacroiliac and hip arthritis: A case report and literature review.

Weitao Wang, Guangzhi Xiao, Qing Han, Jin Ding, Ronghua Xie, Junfeng Jia, Nan Leng, Zhaohui Zheng

Journal: Medicine 2023;102(27):e34099

PMID: 37417608

Abstract

INTRODUCTION

Progressive pseudorheumatoid dysplasia (PPRD) is a rare autosomal recessive genetic disease caused by mutations in the Wnt1-inducible signaling pathway protein 3 gene. PPRD is considered a noninflammatory disease, and involvement of the sacroiliac joint and hip arthritis have not been reported previously.

PATIENT CONCERNS

We report a case of PPRD in an 11-year-old boy, who presented with bilateral pain and swelling in the knees, elbows, and ankles, and bilateral pain without swelling in the shoulders, wrists, knuckles, and proximal and distal interphalangeal joints for the past 5 years. He had been misdiagnosed with juvenile idiopathic arthritis for more than 6 years.

DIAGNOSIS

The correct PPRD diagnosis was made using whole-exome sequencing for Wnt1-inducible signaling pathway protein 3 gene mutations (c.589 + 2T>C and c.721T>G; both mutations have rarely been reported) and magnetic resonance imaging examination; moreover, the latter showed inflammation of the sacroiliac joint and hip joint.

INTERVENTION

The patient was administered supplemental calcium, active vitamin D, and glucosamine sulfate.

OUTCOME

The patient experienced alleviation of joint pain following treatment initiation; however, joint motion improvement was not obvious. Above all, the long-term use of biologic or targeted synthetic disease-modifying antirheumatic drugs in the future was avoided.

CONCLUSION

The findings of the inflammatory aspects in PPRD will enrich our understanding of this rheumatological disease.

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Address: Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.